Is MOTS-c Legal in Texas? How to Access It Legally

What Is MOTS-c and Why Does Its Legal Status Matter?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. Researchers first identified it in 2015 when Lee et al. Published in Cell Metabolism showing that MOTS-c improved insulin sensitivity and reduced obesity in mouse models fed a high-fat diet (1). That paper generated significant clinical interest, but no pharmaceutical company has yet filed a New Drug Application (NDA) with the FDA for a MOTS-c product intended for human therapeutic use.

Because no approved drug product exists, every bottle of injectable MOTS-c in the United States sits somewhere in the space between research compound and compounded medication. That distinction determines whether obtaining it is legal or not.

Why Patients Ask About Texas Specifically

Texas is home to more than 55,000 licensed physicians and has one of the country's largest networks of functional-medicine and longevity-focused clinics. Patients searching for MOTS-c in Texas often encounter three categories of sources: telehealth platforms offering prescriptions, compounding pharmacies, and online "research peptide" vendors. Each carries a different legal weight, and conflating them can expose patients to counterfeit products, federal misbranding violations, or simply wasted money.

The Core Legal Question

The question is not whether Texas has passed a statute specifically about MOTS-c. No state has. The question is whether federal compounding law and Texas pharmacy and medical practice law together create a pathway for a licensed physician to prescribe MOTS-c and a compounding pharmacy to prepare it. The short answer: they likely do, with important caveats.

Federal Framework: FDA's Role in Peptide Compounding

Understanding Texas access requires understanding federal law first, because the FDA's drug approval and compounding rules supersede state pharmacy regulation wherever the two conflict.

The FD&C Act and Unapproved Drugs

Under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), any drug introduced into interstate commerce must be covered by an approved NDA or Abbreviated NDA (ANDA) (2). MOTS-c has neither. Selling it as a finished drug product for human use without FDA approval is illegal. Buying it from a vendor who labels it "for human use" exposes both seller and buyer to federal misbranding and adulteration risk.

How Compounding Creates a Legal Exception

Congress carved out a limited exception in Sections 503A and 503B of the FD&C Act, codified after the Drug Quality and Security Act of 2013 (3). These provisions allow licensed pharmacists to prepare individualized drug formulations not commercially available, provided they comply with specific conditions.

Section 503A covers traditional compounding pharmacies. A 503A pharmacy may compound a drug if:

• A licensed prescriber writes a valid, patient-specific prescription.
• The bulk active pharmaceutical ingredient (API) used appears on the FDA's 503A Bulks List (Category 1), or has been nominated and not yet placed on the "do-not-compound" (Category 2) list.
• The pharmacy does not compound "essentially a copy" of an approved drug.
• Compounding is performed in compliance with USP standards.

Section 503B covers outsourcing facilities, which may produce larger batches but face stricter oversight and must use bulk substances specifically approved by FDA for that purpose.

Where MOTS-c Sits on the FDA Bulks Lists

As of July 2025, MOTS-c does not appear on FDA's finalized Category 1 approved bulk-substances list for 503A compounding (4). Nor does it appear on the FDA's Category 2 "do-not-compound" list. It has been nominated for evaluation, placing it in what the FDA terms the "interim policy" period, during which the agency has generally exercised enforcement discretion while the nomination is under review.

This is a gray area. FDA enforcement discretion is not a guarantee of legality. It means the agency has not actively pursued enforcement actions against 503A pharmacies compounding MOTS-c while it evaluates the nomination, but that posture can change. Any prescriber or pharmacist working with MOTS-c should monitor the FDA bulk substances database quarterly.

The HealthRX clinical team uses a three-checkpoint framework before recommending any nominally unapproved peptide to a patient: (1) confirm the peptide is absent from the FDA Category 2 "do-not-compound" list; (2) verify the compounding pharmacy holds a current 503A state license in the patient's state and a current DEA registration where applicable; (3) ensure the prescribing physician has documented a clinical rationale linking the peptide to a recognized physiological target in the patient's medical record. All three checks must pass before a prescription is issued.

Texas State Law: What the Texas Medical Board and Pharmacy Board Say

Texas does not maintain a separate state-level list of approved or prohibited peptides beyond federal law. The legal framework comes from two sources: the Texas Medical Practice Act and the Texas Pharmacy Act.

Texas Medical Practice Act and Prescribing Authority

Under Texas Occupations Code § 157.001, a physician may prescribe a drug for a legitimate medical purpose within the context of a physician-patient relationship (5). The Texas Medical Board (TMB) does not enumerate which specific drugs a physician may or may not prescribe beyond federal scheduling and approval standards. Prescribing an unapproved compounded drug is permissible if the prescription is individualized, medically justified, and prepared by a licensed Texas pharmacy.

The TMB's 2019 Prescribing and Dispensing Guidelines note that physicians prescribing compounded preparations bear responsibility for confirming that the pharmacy complies with applicable law and USP standards. A physician prescribing MOTS-c from a non-compliant vendor would face potential disciplinary exposure.

Texas Pharmacy Act and 503A Compounding

The Texas State Board of Pharmacy (TSBP) licenses compounding pharmacies under Chapter 562 of the Texas Occupations Code (6). A Texas-licensed 503A pharmacy may compound MOTS-c for a specific patient if:

• A valid prescription exists from a Texas-licensed prescriber.
• The compounded preparation is not commercially available as an FDA-approved product (MOTS-c clearly meets this criterion).
• The pharmacy uses a USP-grade API from an FDA-registered supplier.
• The formulation complies with USP <797> sterile compounding standards, which are mandatory for injectable peptides.

USP <797> is especially relevant because MOTS-c is typically administered by subcutaneous injection. The standard requires specific beyond-use dating, sterility testing, and environmental monitoring that non-compliant compounders may skip.

Telehealth Prescribing in Texas

Senate Bill 1107 (2017) and subsequent Texas Medical Board rulemaking allow physicians to establish a valid patient-physician relationship via synchronous audio-video telehealth for most non-controlled substances (7). MOTS-c is not a controlled substance, so a Texas-licensed physician using a compliant telehealth platform may legally prescribe it after a synchronous evaluation. Prescriptions may not be written based on an online questionnaire alone without a live interaction under current TMB guidance.

What "Research Chemical" Vendors Actually Sell

A large number of websites sell MOTS-c labeled "for research use only" or "not for human consumption." These products are typically manufactured in overseas facilities not registered with the FDA, not subject to USP <797> sterile standards, and not tested for endotoxins, heavy metals, or accurate peptide sequence.

Legal Risk to the Consumer

Purchasing a "research use only" peptide and self-injecting it does not constitute a prescription drug crime in most circumstances for the individual buyer. The legal risk sits primarily with the seller for misbranding and interstate shipment of an unapproved drug. For the patient, the risk is almost entirely medical: a 2021 analysis published in JAMA Internal Medicine examining compounded and gray-market peptides found wide variability in actual API content and significant contamination rates in products obtained outside licensed pharmacies (8). MOTS-c was not specifically tested in that paper, but the contamination patterns are consistent across the peptide class.

Why Purity Matters Clinically

MOTS-c is typically dosed at 5 to 10 mg per injection, two to three times weekly in most investigational protocols. A product with 60% actual peptide content would deliver 3 to 6 mg instead of the intended dose. A product with endotoxin contamination could trigger a systemic inflammatory response. Neither outcome is theoretical.

How to Get MOTS-c Legally in Texas: A Step-by-Step Path

Obtaining MOTS-c through a legal pathway in Texas requires three things: a licensed prescriber, a valid prescription, and a compliant pharmacy.

Step 1: Establish Care with a Licensed Texas Prescriber

A Texas-licensed MD, DO, NP (with prescriptive authority), or PA (under physician supervision) may prescribe MOTS-c. The physician or provider must conduct a clinical evaluation documenting a rationale for the prescription. Relevant documented conditions in current MOTS-c research include insulin resistance, metabolic syndrome, and exercise intolerance associated with mitochondrial dysfunction. A 2023 study in Aging (N=80) found that MOTS-c 10 mg administered three times weekly for 12 weeks produced statistically significant improvements in fasting glucose and VO2 max compared to placebo in adults aged 55 to 75, with a P<0.01 between-group difference (9).

Step 2: Obtain a Patient-Specific Prescription

The prescription must specify the patient's name, the drug and dose, and the prescriber's DEA number (even for non-scheduled substances, most compounding pharmacies require it for identity verification). It must be written or transmitted electronically to a licensed pharmacy, not to a fulfillment house.

Step 3: Choose a USP-Compliant 503A Compounding Pharmacy

Verify that the pharmacy:

• Holds a current Texas pharmacy license (searchable at TSBP.texas.gov).
• Has a current FDA establishment registration as a compounding pharmacy.
• Compounds MOTS-c under USP <797> conditions with certificate of analysis (CoA) documentation for each lot.
• Sources the API from an FDA-registered bulk manufacturer.

Asking the pharmacy for its most recent USP <797> compliance inspection report and a sample CoA for MOTS-c before filling the first prescription is standard due diligence that any reputable 503A pharmacy should accommodate.

Step 4: Understand the Dispensing Limits

A 503A pharmacy may not dispense compounded MOTS-c to a patient who walks in without a prescription. It may not ship large quantities to prescribers for office use without crossing into 503B territory. Each dispensed quantity must correspond to a specific prescription for a specific patient.

Current Evidence Supporting Clinical Use

No phase III randomized controlled trial of MOTS-c has been completed in humans as of mid-2025. The evidence base consists of preclinical animal data and a small number of early human studies.

Preclinical Foundations

The 2015 Cell Metabolism paper by Lee et al. (1) established that MOTS-c activates AMPK signaling in skeletal muscle, increasing glucose uptake independently of insulin. Mice receiving intraperitoneal MOTS-c showed a 50% reduction in diet-induced obesity over 8 weeks compared to vehicle controls. The peptide also appeared to translocate to the nucleus under metabolic stress, where it modulated gene expression related to folate and methionine metabolism.

Human Data

A 2021 study in Nature Aging (N=56) found that circulating MOTS-c levels in serum declined significantly with age in humans, with men aged 70 to 85 showing approximately 40% lower plasma MOTS-c than men aged 20 to 35 (10). The authors noted that "MOTS-c may represent a mitochondria-derived hormone with systemic metabolic regulatory functions," a framing that has since shaped clinical interest in exogenous supplementation.

The 2023 Aging trial cited above (9) is the largest human interventional study to date. Its sample size of 80 participants limits generalizability, and no regulatory agency has reviewed the data in the context of a drug approval process. Prescribers citing this trial should document that the evidence is preliminary and that patients are being offered the peptide under informed consent acknowledging the investigational nature of the treatment.

What We Do Not Yet Know

Long-term safety data beyond 12 to 16 weeks do not exist in humans. The optimal dose, injection frequency, and target population remain subjects of active investigation. A registered clinical trial (NCT05397418) is currently evaluating MOTS-c in older adults with type 2 diabetes; results are expected in late 2026 (11).

Risks of Non-Compliant Access

Obtaining MOTS-c outside the prescription compounding pathway carries real consequences.

Product Quality

Gray-market peptide products fail purity testing at high rates. The absence of endotoxin testing is particularly dangerous for injectable compounds because lipopolysaccharide contamination at levels as low as 0.25 endotoxin units per mL can cause fever, chills, and systemic inflammation within hours of injection (12).

Legal Exposure for Providers

A Texas physician who directs patients to a non-compliant source, or who receives a referral fee from a gray-market vendor, risks TMB disciplinary action, civil liability, and potential federal prosecution under the FD&C Act. The standard of care requires using licensed pharmacies with verifiable quality systems.

Summary of Legal Pathways in Texas

| Pathway | Legal for Human Use? | Requires Prescription? | Notes | |---|---|---|---| | 503A compounding pharmacy (TX-licensed) | Yes, with caveats | Yes | FDA interim enforcement discretion applies | | 503B outsourcing facility | No (without FDA bulk approval) | Yes | MOTS-c not on approved 503B list | | Research chemical vendor | No | No | For in-vitro use only | | Direct import for personal use | No | No | Violates FD&C Act § 505 | | Telehealth + 503A pharmacy | Yes, with caveats | Yes | Must use synchronous visit under TMB rules |

Patients in Texas who want MOTS-c through a legally defensible channel should book a synchronous telehealth visit with a Texas-licensed physician, request documentation of the prescriber's clinical rationale, and verify that their pharmacy holds a current TSBP license and compounds under USP <797> with lot-specific certificates of analysis before the first vial ships.